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1. Introduction
  Bone cancer pain is caused by malignant bone tumor invasion 
or metastasis to bone. At present, it is mainly treated with opioid 
analgesic drugs[1,2]. Due to opioid tolerance, currently there are not 
any good methods to control bone cancer pain, so the quality of life 
of cancer patients has been seriously affected. After the damage of 
nervous system, nerve cell excitability is increased, and discharge 
frequency is added, can cause ectopic discharge. These are closely 
related with activity of voltage-gated sodium channel in sensory 
neurons[3-5].
  Voltage-gated sodium channel Nav1.7 is mainly expressed in 
dorsal root ganglia (DRG). Nav1.7 has its unique character of 
activation and steady-state inactivation, which gives fast activation 
and inactivation, and slow resurrection and close. When small 
subliminal stimulus arrives in nerve cell, it can still work, which 
make the depolarization level of neurons to external stimuli improve, 
then to expand the impulsion, which in turn improves the sensitivity 
to external stimuli[6,7]. Human genetic study shows that gain-of-
function Nav1.7 mutation will cause hereditary erythromelalgia. 
When its function becomes inactivating mutation, it will cause 
congenital insensitivity to pain with anhidrosis[8,9]. Minett et al[10] 
studied that Nav1.7 gene expression in nerve cell of silent rats can 
eliminate the reaction of mechanical pain, inflammatory pain and 
thermal stimulus, but hotplate test and neuropathic pain are not 
affected by it. Gingras et al[11] reported that DRG of Nav1.7 are 
highly expressed in bone cancer pain in the rat, but it is not clear 
that if Nav1.7 level will affect the degree of bone cancer pain.
Objective: To evaluate the effect of down-regulation of Nav1.7 on the activation of astrocytes 
and microglia in DRG of rats with cancer pain, and explore the transmission of the nociceptive 
information. Methods: Lentiviral vector harboring RNAi sequence targeting the Nav1.7 gene 
was constructed, and Walker 256 breast cancer cell and morphine was injected to build the 
bone cancer pain model and morphine tolerance model in rats. Lentiviral vector was injected. 
Rats in each model were divided into 4 groups: model group, PBS group, vehicle group and 
LV-Nav1.7 group. The expression levels of GFAP and OX42 in dorsal root ganglia (DRG) were 
measured. Results: After the animal model was built,the level of Nav1.7, GFAP and OX42 
was improved obviously with the time prolonged, which was statistically significant (P<0.05). 
The expression level of GFAP and OX42 in the DRG in the LV-Nav1.7 group declined 
obviously compared to the model group, PBS group and vehicle group (P<0.05). Conclusions: 
Intrathecal injection of Navl.7 shRNA lentiviral vector can reduce the expression of Nav1.7 
and inhibit the activation of astrocytes and microglia in DRG. The effort is also effective in 
morphine tolerance bone cancer pain model rats.
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  Normally, nerve cells send normal signal to gliocyte through 
ending release neurotransmitter/tempering. Gliocyte can compound 
and release neurotrophic factors such as nerve growth factor and 
brain-derived neurotrophic factor to support the function and 
survival of nerve cell. According to the different stimuli of gliocyte, 
it will produce different cytokines like chemotactic factor, and 
these generations of cytokines are the process of positive feedback, 
which will cause waterfall reaction, and generate and maintain the 
pathological state of pain. In the process of bone cancer pain, it is 
uncertain that whether intervention excitability of nerve cell can 
interdict and reverse the activation of gliocyte, and produce persistent 
effective resistance to damage effect. Therefore, in the present study, 
we built the bone cancer pain model and morphine tolerance model 
in rats. Through intrathecal injection of Nav1.7 shRNA lentivirus, 
down-regulation of Nav1.7 to the activation of astrocytes and 
microglia in DRG of rats with cancer pain was observed, and the 
transmission of the nociceptive information was explored, which will 
provide reference and method for the treatment of bone cancer pain, 
especially morphine tolerance bone cancer pain.
   
2. Materials and methods
2.1 Reagent and instrument
  P12 cell and Walker 256 breast cancer cell were purchased from 
Cell Bank of Chinese Academy of Sciences. Trans1-T1 competent 
cell was purchased from Beijing TransGen Biotech Co., Ltd. pGLV-
U6-GFP vector was purchased from novogen Tech. Co. Ltd. 4 ligase 
was purchased from TaKaRa Biotechnology (Dalian) Co., Ltd. 
Agarose Gel DNA Fragment recovery kit and High Quality Plasmid 
Mini Kit were obtained from Shanghai Xinze Bio-Technique Co. 
Ltd. BCA Protein Quantitative Kit was purchased from Shanghai 
Haling Biological Technology Co., Ltd. Morphine hydrochloride 
was obtained from Shenyang No. 1 Pharmaceutical Co., Ltd. Nav1.7, 
Astrocyte marker GFAP, Microglia markers OX42 and 毬-actin 
primary antibody, secondary antibody of goat anti mouse Nav1.7-
HRP (1:10 000), secondary antibody of goat anti rabbit GFAP-HRP,
secondary antibody of goat anti mouse OX42-HRP, and secondary 
antibody of goat anti mouse 毬-actin-HRP were purchased from 
Abcam. Gel electrophoresis and Vilber Lourmat were purchased 
from Bio-Rad, CA, USA.
2.2. Experimental method
2.2.1. Establishment of bone cancer pain model in rats
  After Walker 256 breast cancer cell grew to exponential growth 
phase, pancreatic enzymes were trypsinized and centrifuged, and 
then culture medium was add to adjust the concentration to 1伊107 
mL until used. 30 SD female rats weighting 200 g were randomly 
divided into three groups: normal group (n=6), PBS group (n=6) 
and model group (n=18). Rats were received intraperitoneal 
anesthesia with 3% pentobarbital sodium, and were fixed limbs 
in supine position, then left hind leg was shaved and the skin was 
sterilized with iodine. Skin of upper tibia was cut for 7 mm, and 
blunt dissection was carried out, with 5 mL syringe for punching in 
tubercle of tibia, and with 1 mL syringe to inject the dilute Walker 
256 cell suspension (control group was injected the equivalent 
normal saline). Then the wound was washed with normal saline 
containing gentamicin. Muscle was sutured with 4-0 surgical suture, 
while skin was sutured with 3-0 surgical suture, then it was sterilized 
with iodine and rats were feeding carefully.
2.2.2. Construction of lentiviral vector
  Primer sequence was designed to connect to linearized shRNA 
vector according to siRNAi sequence targeting the Nav1.7 gene and 
was compounded by Sangon Biotech (Shanghai) Co., Ltd.
  After mixtured primer and annealing buffer to anneal to form 
double strands nucleotide, it was mixed with lentivirus plasmid 
pGLV-U6-GFP vector, T4 ligation buffer and T4 ligase at 4 曟 for 
the night to reaction. 50 mL competent cell Trans1-T1 was placed 
on ice for 5 min, then 3 毺L reaction product was added on ice for 
incubation of 30 min. After that heat shock was performed at 42 曟 
for 1 min, then it was placed on ice for 2 min, and added Luria-
Bertani broth at 37 曟 for 45 min of thermostatic incubation. After 
centrifugation, supernatant was abandoned, and then the resuspended 
fluid was smeared in the LB culture plate with Ammonia benzyl 
resistance. After incubation of 17 h, recombinant monoclonal was 
chosen to inoculate LB culture medium with Ammonia benzyl 
resistance liquid for 17 h incubation, then plasmid was extracted by 
High Quality Plasmid Mini Kit and enzyme validation was carried 
out.
  PC12 cell was inoculated in DMEM medium containing 10% 
FBS and was to cultivate to 80% of the fusion in 5% CO2 incubator 
at 37 曟. Discarded the culture medium, it was washed with PBS, 
trypsinized, centrifuged, resuspended and inoculated to 6 well plate 
with 10暳10
5 cells per well. After 24 h of cultivation, 1 mL entivirus 
liquid was added and 1ml DMEM culture medium was added in 
control group. After 24 h of cultivation, culture medium containing 
lentivirus was discarded, and fresh complete medium was added 
for 96 h continued cultivation. The complete medium of 100 ng/mL 
nerve growth factor was changed, and after cultivation of 12 h, cells 
were collected.
  Cell lysis solution was added to 6-well plate for fully cracking 
cells. Lysis solution was collected to centrifuge tube, added 
isometric SDS-PAGE loading buffer and boiled at 100 曟 for 5 
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min. After cooling on ice and centrifugation, 10% SDS-PAGE was 
used for supernate electrophoresis, and then gel was transferred to 
nitrocellulose membrane under 60V constant pressure. After sealing 
and washing membrane, Nav1.7 (1:1 000) primary antibody or毬
-actin (1:10 000) was added for incubation for the night at 4 曟. 
After washing membrane again, HRP marker GaMIgG (1:10 000) 
was added to incubate at room temperature for 1 h. Then it was 
incubated in reaction liquid at room temperature for 1 h after washed 
with PBS. Exposure to X-ray film, quantity one analysis software 
was used to analyze each specificity of stripe of gray after image 
scanning.
2.2.3. Establishment of animal model
  First of all, subarachnoid catheter of lumbosacral portion in 
rats was carried out. After injection of pentobarbital sodium for 
anesthesia, back of the rat was sterilized, and spine clearance was 
exposed after the skin was cut. L3 vertebral spines were picked up 
with haemostatic forceps, and ligamentum flavum and endorhachis 
were pricked with curved needle. PE-10 catheters were put from 
crevasse into subarachnoid space of about 2 cm. After suture of 
muscle fascia, the other side of catheter was led from the neck and 
back of the rats, which was exposed 2 cm, and the catheter was 
sealed with haemostatic forceps. Rats were feed separately after the 
skin was sutured. After one week of rat model of bone cancer pain, 
NS 10 毺L and 10 毺g morphine were injected respectively twice a 
day with continuous dosing for one week.
2.2.4. Grouping and operation
  After modeling, 90 rats with bone cancer pain were randomly 
divided into three groups: cancer pain+PBS group, cancer pain+ 
empty virus group, cancer pain+Nav1.7 shRNA lentivirus vector 
group. 45 rats with cancer pain morphine tolerance were randomly 
divided into three groups: cancer pain morphine tolerance+PBS 
group, cancer pain morphine tolerance+ empty virus group, and 
cancer pain morphine tolerance+ Nav1.7 shRNA lentivirus vector 
group. After 4 days of modeling, PBS group, empty virus group and 
LV-Nav1.7 group were injected with 10 毺L PBS, 10 毺L empty 
virus and 10 毺L LV-Nav1.7 respectively by intrathecal injection. 
The virus solution was taken out at -80 曟, put in to water bath at 
37 曟 for rewarming, adjusted the titer to 1暳10
9 TU/mL, and then it 
was put on ice for injection.
2.2.5. Detection of Nav1.7 in DRG and effect of protein level 
of GFAP and OX42 in spinal cord
  Rats were deeply anesthetized with 3% pentobarbital sodium and 
prone to the flat board. Rats with bone cancer pain were sacrificed 
with injection of excessive sodium pentobarbital on Day 8, 12 and 
18, while rats with morphine tolerance were sacrificed on Day 24. 
After shaving, the skin of back was cut, spinal muscles on both sides 
were dealed with blunt dissection, and spinal spines and transverse 
process were exposed. After cutting spinous process, vertebral plate 
and transverse process of both sides were removed. L4-6 on the left 
side of the DRG and spinal cord were removed and washed with 
PBS. After weighting, 0.5 mL cell lysis buffer and PMSF were 
added, shaked in homogenizer, and centrifuged at 14 000 r/min
for 10 min. Then working solution was prepared according to 
instructions of BCA Protein Quantitative Kit, and standard curve 
was drawn. After incubation at 37 曟 for half an hour, OD570 was 
identified with ELIASA, and protein concentration was calculated 
according to standard curve. Protein supernate and loading buffer 
were mixed to boil for 10 min, cooled and centrifuged. 12% SDS-
PAGE was used for electrophoresis after collecting protein sample, 
and then gel was transferred to nitrocellulose membrane under 15 
V constant pressure. After 60 min, it was sealed with 5% skim milk 
powder, washed the membrane with PBS, and Nav1.7 (1:1 000), 
GFAP (1:500), OX42 (1:500) or 毬-actin (1:10 000) primary 
antibody were added and incubated for the night at 4 曟. After 
washing with PBS for three times, secondary antibody of Nav1.7 
(1:10 000) IgG (H+L) (HRP-labeled Goat Anti-Mouse IgG (H+L), 
IgG-HRP (H+L) GFAP secondary antibody (1:10 000), secondary 
antibody Goat Anti-Mouse OX42 and secondary antibody Goat anti 
Mouse 毬-actin (1:10 000) were added and incubated for 1 h at room 
temperature, and them washed the membrane again. Exposure to 
X-ray film, Image J was used to analyze the specificity of stripe of 
gray after image scanning.
2.3. Statistical methods
  Data obtained from the experiment were analyzed with SPSSl3.0 
statistical software. t test was used to analyze the protein expression 
level of Nav1.7 protein, GFAP and OX42 in different time points 
among different groups and MWT value in the same time point 
among different groups. Differences are statistically significant at 
P<0.05.
3. Results
3.1. Protein level of Nav1.7 in DRG and GFAP and OX42 in 
spinal cord
  Figure 1 shows the results of Western blot that Nav1.7 was 
not significantly different in control and PBS groups (P>0.05). 
Compared with control and PBS groups, Nav1.7 in model group was 
significantly increased in 8 d. Nav1.7 expression in model group 
was significantly higher in 12 d than that of in the 8 d (P<0.05), 
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and significantly higher in 18 d than that of in 12 d (P<0.05). GFAP 
had no significant difference in control and PBS groups (P>0.05). 
Compared with control and PBS groups, GFAP in model group was 
significantly increased in 12 d (P<0.05). GFAP in model group was 
significantly higher in 18 d than that of in 12 d (P<0.05). OX42 
had no significant difference in control and PBS groups (P>0.05). 
Compared with control and PBS groups, OX42 in model group was 
significantly increased in 8 d (P<0.05). OX42 in model group was 
significantly higher in 12 d than that of in 8 d (P<0.05). There was 
no significant difference compared with 12 d and 18 d (P>0.05).
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Figure 1. Effect of bore cancer pain on Nav1.7, GFAP, and OX42 in rats.
A: Nav1.7 expression level in model group was significantly higher in 8 d 
than that of in PBS group, t=14.117, P=0.000, 12 d higher than 8 d, t=13.223, 
P=0.018, 18 d higher than 12 d, t=10.125, P=0.001. B: GFAP expression 
level in model group was significantly higher in 12 d than that of in PBS 
group, t=12.162, P=0.000, 18 d higher than 12 d, t=10.114, P=0.023. C: 
OX42 in model group was significant increased in 8 d, t=13.963, P=0.000, 
12 d significant higher than 8 d, t=12.193, P=0.000, There was no significant 
difference compared with 12 d and 18 d, t=9.660, P=0.079).
3.2. Effect of shRNA lentiviral vector on Nav1.7 expression 
level of PC12 cells
  After 96 h of infection, compared with control group, protein 
expression level of Nav1.7 in empty virus vector group was slightly 
decreased, but had no significant difference. Protein expression 
level of Nav1.7 in c378 group is significantly decreased, which had 
significant difference (P<0.05) (Figure 2).
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Figure 2. Effect of shRNA lentiviral vector on Nav1.7 expression level of 
PC12 cells.
* indicated statistical significance compared with control group. Compared 
with control group, vehicle group t=9.653, P=0.624; c378 group t=14.629, 
P=0.000.
3.3. Effect of intrathecal injection of Nav1.7 shRNA lentiviral 
vector on protein level of Nav1.7 in DRG and GFAP and 
OX42 in spinal cord in rats
  Figure 3 showed the results of Western blot that after modeling 
in different time point, expression level of Nav1.7 in vehicle group 
had no significant difference compared with that of in PBS group 
(P>0.05). After modeling of 12 d, 18 d, expression level of Nav1.7 
in LV-Nav1.7 group was significant lower than that of in PBS 
group, which had significant difference (P<0.05). After modeling, 
expression level of Nav1.7 in PBS and vehicle groups were increased 
with the time prolonged, and both had significant difference 
(P<0.05), while expression level of Nav1.7 in LV-Nav1.7 group had 
no significant difference in different time point (P>0.05).
  After modeling, compared with model group, protein level of OX42 
in PBS and vehicle groups in different time point had no significant 
difference (P>0.05), while OX42 in LV-Nav1.7 group was significant 
decreased (P<0.05). In addition, along with time, OX42 level in LV-
Nav1.7 group had a downward trend, but compared with normal rats, 
it was still significantly increased in different time point (P<0.05).
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Figure 3. Effect of intrathecal injection of Nav1.7 shRNA lentiviral vector on 
protein level of Nav1.7 in DRG and GFAP and OX42 in spinal cord in rats.
A: expression level of Nav1.7 in LV-Nav1.7 group was significant lower in 
12 d and 18 d compared with PBS group, 12 d, t=10.088, P=0.021, 18 d, 
t=13.723, P=0.000; B: expression level of GFAP in LV-Nav1.7 group was 
significant lower in 12 d and 18 d compared with PBS group, 12 d, t=12.088, 
P=0.007, 18 d, t=13.533, P=0.000. Compared with control group, 12 d, 
t=10.332, P=0.020, 18 d, t=11.360, P=0.009. C: expression level of OX42 
in LV-Nav1.7 group was significant lower in 12 d and 18 d compared with 
PBS group, 12 d, t=11.673, P=0.008, 18 d, t=12.179, P=0.003. Compared 
with control group, 8 d, t=13.780, t=0.000, 12 d, t=13.582, P=0.000 8, 18 d, 
t=11.652, P=0.013).
3.4. Effect of intrathecal injection of Nav1.7 shRNA lentiviral 
vector on protein level of Nav1.7 in DRG and GFAP and 
OX42 in spinal cord in morphine tolerance bone cancer pain 
model rats
   
  After modeling for 24 h, expression level of Nav1.7, GFAP and 
OX42 in vehicle group had no significant difference compared with 
PBS group (P>0.05). Expression level of Nav1.7 and GFAP in LV-
Nav1.7 group was significantly lower than PBS group, which had 
significant difference (P<0.05). Expression level of OX42 in LV-
Nav1.7 group had no significant difference compared with PBS 
group and vehicle group (P>0.05) (Figure 4).
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0R
el
at
iv
e 
le
ve
l o
f 
pr
ot
ei
n
PBS group     vehicle group        LV-Nav1.7 group
Nav1.7                             GFAP                               OX42
 
Figure 4. Protein expression level of Navl.7 in DRG of morphine tolerance 
bone cancer pain model rats and GFAP and OX42 in spinal cord after the 
decrease of Navl.7 expression.
Compared with LV-Nav1.7 group, expression level of Nav1.7 in PBS group 
t=14.664, P=0.001; expression level of GFAP t=13.116, P=0.000.
4. Discussion
  Navl.7 is more slowly in closed-state inactivation and resurrection 
and has specific expression character. Currently, studies have 
shown that Navl.7 has closely relation with mechanical pain and 
inflammatory pain[12-14]. However, there is still no conclusion that 
if it involves in and affect neuropathic pain. Inflammatory pain and 
neuropathic pain are coexisted in cancer pain. It is still not clear 
that whether the expression level of Navl.7 influence cancer pain. 
The present study detected the change of pain behavior in DRG 
of rats with cancer pain and morphine tolerance bone cancer pain 
before and after down-regulation of Nav1.7, and verified that down-
regulation of Nav1.7 expression level in DRG can significantly 
relieve the bone cancer pain of the rats.
4.1. Research of Nav1.7
  Navl.7 is the gene SCN9A coding in the distribution of 
transmembrane protein of human peripheral nervous system. After 
mutations, Nav1.7 will cause some diseases associated with pain. 
Primary Erythermalgia (PE) is a kind of autosomal dominant disease, 
which is caused by function enhancement of Navl.7 through SCN9A 
gene mutation. Black et al[16] found that patients with chronic pain 
disease were caused by the polymorphism of SCN9A, and healthy 
women who have this genetic characteristic are more sensitive to 
pain. Through animal experiment, Shields et al[17] confirmed that 
Navl.7 current has relationship with superexcitation of esthesioneure 
and communication of postsynaptic spinal pain pathways. Yang et 
al[18] reported that polypeptide 毺-SLPTX-Ssm6a extracted from 
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centipede can inhibit Navl.7 well, and can relieve pains caused by 
chemicals and temperature in rodent models. Currently, it is reported 
that Nav1.8 and Nav1.9, which belong to the same family of Nav1.7, 
are closely related with bone cancer pain in the expression level of 
DRG[19,20], but it is unknown that whether the level of Nav1.7 will 
affect the degree of bone cancer pain.
4.2. Relief of bone cancer pain in rats by intrathecal injection 
of Nav1.7 shRNA slow virus vector
  Tumor in the bone growth stimulates osteoclast to lead to bone 
destruction and pull of periosteum, causing ischemia and peripheral 
nerve compression, and then induced microglia activation. It is found 
that in rat model of bone cancer pain, the spinal cord and carcinoma 
ipsilateral limb has large astrocyte proliferation, and gliocyte can be 
activated by morphine and involved in morphine tolerance, which 
showed that activation of astrocyte may be related to the maintaining 
of pain[21,22]. General studies detect astrocytes and microglia 
activation marker glial fibrillary acidic protein (GFAP) and OX42 to 
determine the degree of activation of two cells[23, 24]. Resuts showed 
that expression level of Nav1.7 and the two gliocyte markers in 
bone cancer pain models in rats were significantly increased along 
with the prolonged time. Although the expression level of GFAP in 
rats with intrathecal injection of Nav1.7 was increased, it was still 
significantly lower than bone cancer pain models in rats. Nav1.7 and 
OX42 were decreased along with the prolonged time. This showed 
that intrathecal injection of Nav1.7 shRNA lentiviral vector inhibited 
the expression of Navl.7. Althrough the variation trend of expression 
of GFAP and OX42 was not changed, it obviously slowed down 
the increasing speed of GFAP, accelerated the decreasing speed 
of OX42, and reduced the activation of astrocyte and gitter cell. 
The increase of expression of Nav1.7 in rats with bone cancer pain 
is probable due to the oppression and damage of tumor on local 
nerve fibers transmits traumatic information to DGR nerve cell 
repeatedly and stimulates continuous depolarization and activation 
of DGR nerve cell to promote the increase of dependency of Nav1.7 
expression time.
4.3. Relief of morphine tolerance bone cancer pain model rats 
by intrathecal injection of Nav1.7 shRNA slow virus vector
  Opioid drugs are the main way for the drug treatment of controlling 
cancer pain. As the final section of three stage treatments of cancer 
pain, opioid drugs will bring great pain to body and mind of the 
cancer pain patients once they produce morphine tolerance[25]. In the 
present study, we established morphine tolerance bone cancer pain 
model rats to explore whether down-regulation of Nav1.7 expression 
level can relieve the bone cancer pain of morphine tolerance rats 
through intrathecal injection of Nav1.7 shRNA lentiviral vector. 
The results showed that after 24 d of injecting Nav1.7 shRNA 
lentiviral vector, the expression level of Navl.7, GFAP and OX42 
were significantly decreased, which indicated that the decrease of 
Nav1.7 expression can inhibit the activation of gliocyte. This may be 
because of the directly abirritation of Nav1.7 shRNA lentiviral vector 
and the reversion of astrocyte activation, which relieve the morphine 
tolerance to ease the pain.
4.4. Insufficient and prospect
  Our work is not perfect. We only detected the expression of glial 
cell activation of related proteins in rats with bone cancer pain in 24 
d of Nav1.7 silence. But it is unknown how long the anti-nociceptive 
effect of an intrathecal injection of Navl.7 shRNA lentiviral vector 
will maintain. Therefore, in the later study, we will further detect the 
timeliness. We will also further validate the effect of voltage gated 
sodium channel NaV 1.7 on bone cancer pain rats by detecting the 
behavioral change of the rats.
  In conclusion, a single intrathecal injection of Navl. 7 shRNA 
lentiviral vectors can reduce rats bone cancer pain, and voltage gated 
sodium channel NaV 1.7 may become the drug target of selective 
treatment of pain.
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